Antibacterial Action of Curcumin against Staphylococcus aureus: A Brief Review by Teow , Sin Yeang et al.
Review Article
Antibacterial Action of Curcumin against
Staphylococcus aureus: A Brief Review
Sin-Yeang Teow,1 Kitson Liew,2 Syed A. Ali,3 Alan Soo-Beng Khoo,2,4 and Suat-Cheng Peh1,5
1Sunway Institute for Healthcare Development (SIHD), Sunway University, 47500 Bandar Sunway, Selangor Darul Ehsan, Malaysia
2Molecular Pathology Unit, Cancer Research Centre (CaRC), Institute for Medical Research (IMR), 50588 Jalan Pahang,
Kuala Lumpur, Malaysia
3Advanced Medical and Dental Institute (AMDI), Universiti Sains Malaysia (USM), 13200 Kepala Batas, Pulau Pinang, Malaysia
4Institute for Research, Development and Innovation, International Medical University (IMU), 57000 Bukit Jalil,
Kuala Lumpur, Malaysia
5Anatomical Pathology Department, Sunway Medical Centre, 47500 Bandar Sunway, Selangor Darul Ehsan, Malaysia
Correspondence should be addressed to Sin-Yeang Teow; ronaldt@sunway.edu.my
Received 31 August 2016; Accepted 24 October 2016
Academic Editor: Sukla Biswas
Copyright © 2016 Sin-Yeang Teow et al.This is an open access article distributed under the Creative CommonsAttribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Curcumin, the major constituent of Curcuma longa L. (Zingiberaceae family) or turmeric, commonly used for cooking in Asian
cuisine, is known to possess a broad range of pharmacological properties at relatively nontoxic doses. Curcumin is found to be
effective against Staphylococcus aureus (S. aureus). As demonstrated by in vitro experiment, curcumin exerts even more potent
effects when used in combination with various other antibacterial agents. Hence, curcumin which is a natural product derived
from plant is believed to have profound medicinal benefits and could be potentially developed into a naturally derived antibiotic in
the future. However, there are several noteworthy challenges in the development of curcumin as a medicine. S. aureus infections,
particularly those caused by the multidrug-resistant strains, have emerged as a global health issue and urgent action is needed.This
review focuses on the antibacterial activities of curcumin against both methicillin-sensitive S. aureus (MSSA) and methicillin-
resistant S. aureus (MRSA). We also attempt to highlight the potential challenges in the effort of developing curcumin into a
therapeutic antibacterial agent.
1. Introduction
Curcumin or diferuloylmethane is the major phytochemical
of Curcuma longa L. (Zingiberaceae family), which is com-
monly known as turmeric. Curcumin is the polyphenolic
compound that gives the yellow colour of the herb. Turmeric
is mainly cultivated in tropical and subtropical regions and is
mainly produced by India. Traditionally, it has been used to
flavour food, dye cloths, and treat various human ailments [1].
Curcumin is extracted from turmeric by solvent extraction
(preferably with ethanol) through various methods (e.g.,
Soxhlet, ultrasonic, microwave, and supercritical carbon dio-
xide) followed by purification via column chromatography
[2, 3]. Ever since the identification of curcumin as the main
constituent of turmeric, multiple pharmacological activi-
ties of curcumin that include antimicrobial, antidiabetic,
anti-inflammatory, anticancer, and antioxidant have been
reported [4–6]. More excitingly, when combined with other
drugs, curcumin has been found to enhance the effects of
antibacterial [7–9], antifungal [10, 11], anticancer [12, 13], and
antioxidant [14, 15] activities.
Curcumin usually exhibits low to no toxicity at the active
doses. A systematic review from theMEDLINE computerized
database (1966 to 2002) has shown that curcumin is safe when
consumed up to 8 g each day consecutively for 3 months in a
phase I human trial that involved 25 subjects [16]. Similarly,
the dose of 8 g per day was safe when used in combination
with gemcitabine that showed marked therapeutic effects in
pancreatic cancer patients [17, 18]. Interestingly, curcumin
is also able to reverse the Aflatoxin B1-induced toxicity and
iron-overloaded liver toxicity in rats [19–21]. Despite being
extensively studied, the exact mechanism(s) of curcumin’s
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multiple biological and pharmacological activities remains
to be explored. Based on the available literature, there are
two hypotheses describing the poly-pharmacological effects
of curcumin. First, curcumin is known to act on multiple
targets [4, 5, 22–24], hence having diverse roles in regulating
various cellular processes. Secondly, products resulting from
the curcumin degradation have been shown to be highly
diverse depending on the chemical or biochemical reactions
involved [25–27]. Most of these products are stable and
function differently that may lead to the multiple effects.
The most studied activity of the curcumin in the past 10
years is the anticancer effects [28]. However, the first paper
describing the biological action of curcumin was its antibac-
terial activity against various bacteria: S. aureus, Trichophy-
ton gypseum, Salmonella paratyphi, and Mycobacterium
tuberculosis [29]. To date, studies on the antibacterial activity
of curcumin that indicate inhibition properties of a wide
range of bacteria are increasingly documented [6, 23, 30].
Recent publications have also reported that curcumin is
active against a plethora of drug-resistant bacterial strains
[8, 9, 31, 32]. S. aureus infection is a major problem in many
developing countries, especially in hospitals where theMRSA
spreading is difficult to control [33]. Over the years, themulti-
drug-resistant S. aureus infection has increased the global
morbidity andmortality [34, 35].Due to the difficulty in treat-
ing the infection, it has consequently imposed an elevating
burden on healthcare resources [36–38]. Cumulative findings
in recent years have shown that curcumin is active against
both MSSA and MRSA [8, 9, 30, 32, 39, 40]. In view of the
need for a more efficacious and safe therapeutic modality
towards the drug-resistant S. aureus, we discuss the reported
antibacterial activities of curcumin against S. aureus and
its potentials and limitations to be developed into a potent
antibiotic.
2. Curcumin-Mediated Inhibition of S. aureus
Curcumin inhibits the growth of both Gram-positive and
Gram-negative bacteria [6, 23, 30]. S. aureus is one of the
Gram-positive strains that is susceptible to curcumin-media-
ted inhibition. S. aureus is a pathogen that causes various
infections including infective endocarditis (IE), bacteremia,
skin and soft tissue, osteoarticular, and pleuropulmonary
infections [33]. Over the years, S. aureus has evolved and
developed multiple strategies to evade human immune sys-
tem and to resist antibiotics treatment. This has given rise
to the evolution of MRSA, and the emergence of healthcare-
associated (HA) and community-associated (CA) MRSA has
caused amajor problem to the human society [45, 46]. In this
section, we discuss the past and current works that show the
curcumin-mediated killings of MSSA and MRSA (summa-
rized in Table 1).
Mun et al. [9] showed that the minimal inhibitory conc-
entrations (MICs) of curcumin against 10 strains of S. aureus
(including 2 ATCC MSSA and MRSA standard strains, 4
MRSA clinical isolates, and 4 MRSA from culture collection)
ranged from 125 to 250 𝜇g/mL while a study by Wang et al.
[40] showed the MIC of 256𝜇g/mL against MSSA. Using a
broth microdilution assay, our group [8] also showed that
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Figure 1: Chemical structures of antibacterial curcumin analogues
against S. aureus. Upper panel shows the structure of curcumin-1
[30, 41] while the lower panel shows the metal complexes of cur-
cumin, indium curcumin [42, 43]. The chemical structures above
were drawn using a free online tool, ChemWriter (http://chemwriter
.com/).
250 𝜇g/mL curcumin was required to kill the two ATCC
MSSA (#25923) and MRSA (#43300) strains. However,
another study demonstrated that theMICs against the ATCC
standard MSSA and MRSA were 219 and 217 𝜇g/mL, respec-
tively, that are slightly lower than the former study [47].
Recently, Kali et al. [48] showed the mean curcumin MIC
of 126.9 𝜇g/mL against 15 Gram-positive bacterial isolates
including thirteen S. aureus and two Enterococcus faecalis.
Nonetheless, this study is not used for comparison in Table 1
because the obtained MIC might not be representative for
curcumin’s effect against S. aureus as the study was carried
out in combination with Enterococcus faecalis.
A more potent inhibition was achieved when curcumin-
1 (CUR-1), a major component of commercial preparations
of curcumin (purity > 98%), was used against S. aureus. The
chemical structure of curcumin-1 is shown in Figure 1. Tyagi
et al. [30] showed that the curcumin-1 was active against
MSSA at concentration of as low as 25𝜇M (equivalent to
9.21 𝜇g/mL), as it killed 50% of the bacteria after 2 hr incuba-
tion. The activity was time- and dose-dependent, and 100%
killing was achieved at 50𝜇M (equivalent to 18.42𝜇g/mL)
after 2 hr exposure [30]. In contrast, Sasidharan et al. [41]
showed that the same compound had a MIC of 250𝜇g/mL
against S. aureus, which is comparable to the native cur-
cumin [8, 9]. In an in vivo mouse model, administration of
100mg/kg curcumin was shown to protect the mice infected
with both MSSA and MRSA from pneumonia by targeting
the 𝛼-hemolysin (HIa) protein of S. aureus [40]. In summary,
the curcumin MICs against S. aureus ranged from 18.42 to
256𝜇g/mL (refer to Table 1). The variation could be due to
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Table 1: Antibacterial activity of curcumin against S. aureus.
Compound (solvent) MIC (𝜇g/mL) S. aureus strain Test method Reference
Curcumin (DMSO) 187.5 MSSA (ATCC 25923) Broth macrodilution [42]
Indium curcumin (DMSO) 93.8
Curcumin (DMSO) 125–250
MSSA (ATCC 25923)
MRSA (ATCC 33591)
MRSA (4 Clinical isolates)
MRSA (4 from CCARM)#
Broth microdilution [9]
Curcumin-1 (DMSO) 250 MSSA (MTCC 902)∗ Broth microdilution [41]
Curcumin (DMF) 250
MSSA (ATCC 25923)
MRSA (ATCC 43300)
MSSA (1 Clinical isolates)
MSSA (10 Env. isolates)
Broth microdilution [8]
Curcumin-1 (DMSO) 18.42 MSSA (ATCC 29213) Colony counting method [30]
Curcumin (ethanol) 219 MSSA (ATCC 29213) Broth macrodilution [47]
217 MRSA (ATCC 43300)
Curcumin (ethanol) 125 MSSA (ATCC 25923) Broth macrodilution [49]
Curcumin (DMSO) 256 MSSA (USA 300)MSSA (8325-4) Broth microdilution [40]
#CCARM: culture collection of antimicrobial resistant microbes.
∗Purchased fromMicrobial Type Culture Collection Centre (MTCC), IMTECH, Chandigarh, India.
Env.: environmental.
(i) strain difference (i.e., MRSA versus MSSA); (ii) source of
bacterial strains (i.e., ATCC standard strains versus clinical
isolates); (iii) type of antibacterial assay (i.e., disk diffusion
versus brothmicrodilution); and (iv) type of curcumin and its
solvent (i.e., commercial compound versus in-house purified
compound). Overall, the cumulative findings showed that
there is no difference of MICs against MSSA and MRSA,
suggesting that the sensitivity towards curcumin treatment
is not altered by the multidrug resistance machinery in S.
aureus.
There have been several explanations on how curcumin
acts and kills the bacteria which are illustrated in Figure 2.
Rai et al. [44] have demonstrated that curcumin interacts
with FtsZ (prokaryotic homologue of eukaryotic cytoskeletal
protein tubulin) in vitro and inhibits the assembly of FtsZ
protofilaments in Bacillus subtilis 168. Although it has not
been examined directly on S. aureus, it is believed that inhibit-
ing the assembly dynamics of FtsZ is one of the main mech-
anisms of curcumin in inhibiting bacterial cell proliferation.
FtsZ is also believed to be a novel target for the development
of antibacterial drugs against S. aureus. [63, 64]. Mun et al.
[32] showed that the antibacterial action of curcumin against
both MSSA and MRSA was markedly enhanced when used
in combination with ATPase inhibitors and mild detergents
that compromise ATP-binding cassette (ABC) transporters
and cytoplasmic membrane integrity, respectively. The same
study has also shown that curcumin binds to peptidoglycan
(PGN), and the increasing concentrations of PGN block the
curcumin antibacterial activity. Tyagi et al. [30] also showed
that curcumin-1 inhibited S. aureus growth by perturbing
the bacterial membrane integrity. In this study, the bacterial
membrane of S. aureus was examined using two fluores-
cent probes: propidium iodide and calcein. The membrane
leakage upon exposure to curcumin was also evaluated by
fluorescence and scanning electron microscopies. Although
existing evidence suggests that curcumin inhibits S. aureus
mainly by damaging the bacterial membrane, further inves-
tigation is required to identify additional bacterial target
proteins besides FtsZ and PGN. This is important not only
to enhance the understanding of the curcumin interaction
with its target proteins, but also to further improve the
activity of curcumin against S. aureus, particularly theMRSA
strains. Similar studies should also be performed on the
curcumin derivatives such as curcumin-1 (curcumin with
highest purity >98%) and indium curcumin (metal complex
with curcumin) which have shown more potent antibacterial
effects than the native curcumin. The chemical structures of
curcumin-1 and indium curcumin are shown in Figure 1.
3. Synergism of Curcumin with
Antibiotics against S. aureus
In addition to showing potent antibacterial activity when
used alone, curcumin also exerts marked activity against S.
aureus when used at subinhibitory dose in combination with
various other antibiotics [8, 9, 31, 32].These findings are inter-
esting since curcumin is naturally derived from turmeric,
which is one of the major ingredients of Asian cuisine [1,
23]. Of note, crude turmeric extracts have previously shown
marked antibacterial activities against S. aureus [6, 65, 66].
This section discusses the synergistic antibacterial activity
of curcumin with antibiotics against MSSA and MRSA.
Table 2 summarizes studies that demonstrated the synergism
of antibiotics-curcumin. In this table, we include the infor-
mation of curcumin type, solvent, and concentration, type of
bacteria-killing assay, and S. aureus strains for comparison.
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Figure 2: The potential mechanisms underlying the antibacterial effect of curcumin against S. aureus. Circle-shaped arrow indicates
binding whereas blocked arrow represents inhibition. (a) Curcumin may bind into FtsZ proteins, thereby inhibiting the assembly of FtsZ
protofilaments. This, in turn, suppresses the formation of Z-ring leading to inhibition of cytokinesis and bacterial proliferation [44]. (b) In
the case of MRSA, curcumin could inhibit the mecA gene transcription, causing reduced expression of PBP2𝛼 proteins. As a result, MRSA
can be sensitized towards the antibacterial action of 𝛽-lactam antibiotics such as Penicillin and Methicillin [32]. (c) The binding between
curcumin and peptidoglycan on S. aureus cell wall could trigger damage on the cell wall and membrane, leading to cell lysis of S. aureus
[30, 32].
Table 2: Synergism of curcumin against S. aureus.
Compound (solvent) Subinhibitoryconcentration Antibiotics S. aureus strain Test method Reference
Curcumin (not
reported) 500 𝜇g/disc
Cefixime
Cephotaxime
Vancomycin
Tetracycline
MSSA (1 clinical isolate) Disk diffusion [31]
Curcumin (DMSO)
Checkerboard
(various serial
dilutions)
Oxacillin
Ampicillin
Ciprofloxacin
Norfloxacin
MSSA (ATCC 25923)
MRSA (ATCC 33591)
MRSA (1 clinical isolate)
Broth microdilution [9]
Curcumin-1 (DMSO)
Checkerboard
(various serial
dilutions)
Cefaclor
Cefodizime
Cefotaxime
MSSA (MTCC 902)∗ Broth microdilution [41]
Curcumin (DMF) 25𝜇g/mL
Gentamicin
Amikacin
Ciprofloxacin
MSSA (ATCC 25923)
MRSA (ATCC 43300)
MSSA (1 clinical isolate)
MSSA (10 environ. isolates)
Disk diffusion &
broth microdilution [8]
Curcumin (DMSO) 32 𝜇g/mL
Penicillin
Erythromycin
Ciprofloxacin
MSSA (ATCC 25923)
MSSA (13 clinical isolates) Disk diffusion [48]
∗Purchased fromMicrobial Type Culture Collection Centre (MTCC), IMTECH, Chandigarh, India.
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The first study that reported the synergism of curcumin
against S. aureus was seven years ago by Moghaddam et al.
[31]. Using a disk diffusion method, Moghaddam et al. [31]
showed that 500𝜇g/disc of curcumin exerted synergistic
antibacterial effect on the MSSA when used in combination
with four antibiotics. Combinationwith cefotaxime, cefixime,
tetracycline, and vancomycin resulted in increase of inhibi-
tion zone of 52.6, 24.9, 26.5, and 24.4%, respectively.This was
then followed by Mun et al. [9] study in 2013 that showed
curcumin’s synergismwithOxacillin, Ampicillin, Ciprofloxa-
cin, and Norfloxacin against the MRSA.This study employed
checkerboard broth microdilution assay method to deter-
mine the synergistic activity. This method allows more stan-
dardised testing and is less laborious and suitable for studies
with multiple concentrations of test compounds [67]. Other
studies also showed the synergistic antibacterial effect of cur-
cumin against both MSSA and MRSA when used in combi-
nation with antibiotics such as Cefaclor, Cefodizime, Cefo-
taxime, Gentamicin, Amikacin, Penicillin, and Erythromycin
(refer to Table 2). Based on reported findings, the curcumin
synergism in combination with antibiotics appears to be rela-
tively nonspecific. Antibiotics classes that have shown syn-
ergism with curcumin include 𝛽-lactams, Cephalosporins,
Aminoglycosides, Glycopeptides, Tetracyclines, and Fluoro-
quinolones. This might due to the multitargeting action of
curcumin or their undetermined breakdown products as
pointed out in the previous section. More studies are needed
to evaluate the mechanism of curcumin synergism based on
the different classes of antibiotics. In addition to antibacterial
action, curcumin also reverses the drug resistance when used
in combinationwith other anticancer agents such as cisplatin,
5-fluorouracil, oxaliplatin, and doxorubicin in multiple types
of cancer cells including breast [68], colon [69], head and
neck [70], and ovary [71]. The curcumin may have acted on
the target or pathway related to the development of drug
resistance, hence restoring the killing effect of the drugs [72,
73]. This may be one of the mechanisms on how curcumin
enhances the effect of antibacterial drugs, especially when
they are targeting S. aureus-infected human cells.
In recent years, MRSA infection has emerged as a serious
infection due to its multidrug resistance (MDR) especially
in the hospital setting [74]. The MRSA infection may spread
rapidly especially when the disease is not well controlled.
Curcumin exhibits potent activity against MRSA, not only
when used alone, but also in combination with other antibi-
otics. In an effort to understand the curcumin’s anti-MRSA
effect, Mun et al. [32] showed that the Tris and Triton X-100
inhibited the bacterial growth to 63% and 59%, respectively,
when used together with curcumin. This suggests that bacte-
rial membrane permeability is partly responsible in regulat-
ing the antibacterial efficacy of curcumin against MRSA.The
same group has also shown that ATPase inhibitors (DCCD
and NaN
3
) which block the ATP-binding cassette (ABC)
enhanced the MRSA killing when used together with cur-
cumin. The importance of membrane permeability/integrity
in curcumin effect was also confirmed when the increase of
peptidoglycan (PGN) concentration successively blocked the
curcumin antibacterial activity [32]. These findings suggest
that any drug or inhibitor that primarily acts on the bacterial
membrane has higher chance of showing enhanced activity
when used together with curcumin. It is also noteworthy that
the expression of Penicillin-binding protein 2𝛼 (PBP2𝛼), a
protein responsible in conferring resistance towards𝛽-lactam
antibiotics, was downregulated in MRSA upon curcumin
treatment [32]. This protein which is encoded by MecA, a
nonnative gene in MRSA has significantly reduced affinity
for 𝛽-lactam antibiotics such as Methicillin and Penicillin.
Cell-wall biosynthesis, the target of 𝛽-lactam, could therefore
carry on in MRSA despite the presence of potent doses of
these antibiotics [75]. The detailed mode of action of cur-
cumin in inhibiting PBP2𝛼 expression in MRSA is not clear
at this juncture. It is plausible that curcumin may act on the
transcription of MecA gene, thereby blocking the expression
of PBP2𝛼 protein (Figure 2).
In addition to antibiotics, there are evidences showing
that curcumin augments the activity of other natural com-
pounds against MSSA and MRSA. Balan et al. [76] demon-
strated that combination of curcumin and whey proteins
markedly inhibited S. aureus growth in vitro. Sharma et al.
[77] have also previously reported the combination effect of
curcumin with several phytochemicals such as cinnamalde-
hyde, ellagic acid, and eugenol against Staphylococcus epider-
midis (S. epidermidis), which is closely related to S. aureus.
The combination activities as such against S. aureus remain
to be investigated. Indeed, there have been many studies
showing the potent antibacterial action of other natural com-
pounds against S. aureus such as thymoquinone [78], rhein
[79], emodin [80], silibinin [81], osthol [82], tannic acid [83],
and epigallocatechin gallate [84]. These findings warrant the
potential use of abovementioned compounds in combination
with curcumin against S. aureus.
4. The Challenges of Using Curcumin
as Antibiotic
Cumulative findings suggest that curcumin has broad-spec-
trum antibacterial activities and has synergistic effects with
other antibiotics in combination therapies in vitro [1, 6, 85].
Curcumin has also shown potent antibacterial action in the
mouse model [40]. Nonetheless, the curcumin antibacterial
activity has never been evaluated in clinical trials with an aim
of using it as a future antibiotic. In this section, we discuss
the underlying challenges from the clinical perspectives in
developing curcumin into a potential antibiotic.
While curcumin is known to possess the pharmacological
activities at relatively low doses, several studies have evi-
denced some cytotoxicity of curcumin [50–54, 86]. The first
study that demonstrated the curcumin toxicity was by Good-
pasture and Arrighi [50].They showed that turmeric resulted
in an induction of chromosome aberrations in tested cell
lines starting from 10 𝜇g/mL. Other studies have also shown
the toxic effects of curcumin mainly on the DNA damage
and chromosome aberrations [51–53]. While DNA alteration
is the starting point of carcinogenesis, the use of curcumin
under abovementioned conditionsmight be an issue. In other
words, curcumin treatment may cause cancers even though
the anticancer action of curcumin is well documented. In
1993, a study has concluded that turmeric oleoresin (turmeric
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extract containing 79–85% of curcumin) has carcinogenic
property in rats and mice [54]. Mice taking 0.2mg/kg body
weight of curcumin daily average were found to have carci-
nomas in their small intestines. Curcumin has also shown
to promote lung cancer in another study [55]. The tumour-
promoting activity of curcumin has been linked to the induc-
tion of reactive oxygen species (ROS) production such as
superoxide anion and hydrogen peroxide [87–89].
As curcumin is an active iron chelator, it may potentially
affect systemic iron metabolism especially those who have
suboptimal iron status [56]. Furthermore, curcumin has been
reported to block the enzymes that metabolize drugs such as
cytochromeP450s [57, 58].Thismay lead to the accumulation
of nonmetabolized drugs in blood and result in undesired
toxicity. In human, nonetheless, the side effects of curcumin
have been relatively mild. A human trial has shown that
curcumin ranging from 0.9 to 3.6 g per day up to 4 months
only caused some adverse effects that included nausea, diar-
rhea, and increased serum alkaline phosphatase and lactate
dehydrogenase [90]. In 2010, Balaji and Chempakam [91]
have predicted a few toxigenic and potent compounds from
turmeric using a cost-effective cheminformatics approach.
This method can be adopted to select the effective but non-
toxic curcumin or its derivatives for further biological studies.
However, the selected compound has to be evaluated in a
long-term study at its active dose against S. aureus in order to
confirm the safety of using curcumin as a potential antibiotic.
Curcumin is usually extracted from turmeric plant
mainly by solvent extraction followed by column-based
purification [2, 3]. Curcumin is sparingly soluble in water
(<0.1mg/mL) and is mainly dissolved in organic solvents
such as DMSO, DMF, or ethanol (Tables 1 and 2). This may
be the major concern when it is administered into human
system as human plasma is composed of 92% of water. The
water-insoluble nature may affect curcumin bioavailability
and hence affect its pharmacological potential [26, 27, 61].
To this end, several methods have been developed in recent
years to circumvent the poor solubility and stability of cur-
cumin, therebymaximizing its pharmacological or biological
actions. For example, it has been reported that the use of heat
could enhance the curcumin solubility [59, 60]. Kurien et al.
[59] have reported the improved water solubility of curcumin
from 0.6 to 7.4 𝜇g/mL, without displaying heat-mediated des-
truction of the chemical structure. Development of curcumin
bioconjugates has also shown to be an effective method of
enhancing the curcumin solubility. For instances, conjuga-
tion of curcumin with hyaluronic acid formed micelles in
aqueous phase at physiological pH and appeared to be non-
toxic [92]. Dey and Sreenivasan have also conjugated cur-
cumin with alginate, a natural polysaccharide product, in
order to increase its stability and bioavailability [93]. Other
macromolecules that could serve as carrier systems for cur-
cumin include beta-casein [94], chitosan/Tween 20 [95],
emulsomes [96], sodiumcaseinate [97], and albumin [98, 99].
The development of curcumin nanoformulations has been
extensively reviewed in light of its anticancer action [100–
102].While increasing number of curcumin nanoformulation
is being introduced into the therapeutic field, it is important
to ensure that the bioconjugates or nanoformulations do not
Table 3: Challenges of curcumin use in clinical setting.
Challenge References
Cytotoxicity
DNA damage and chromosome aberrations [50–53]
Carcinogenesis
Promote tumour formation in vivo [54, 55]
Iron chelation
Alter systemic iron metabolism [56]
Enzyme inhibition
Inhibit drug-metabolizing enzymes [57, 58]
Solubility
Hydrophobic nature does not support water
solubility [59, 60]
Bioavailability
Degradation by plasma protease and
nonspecific protein binding [26, 27, 61, 62]
diminish the antibacterial effects of curcumin at the expense
of improved bioavailability in order to develop them into
effective antibiotics in the future.
In addition to potential toxicity, poor solubility, and
low bioavailability, curcumin encounters multiple challenges
when it is administered either through oral or intravenous
route due to the nature of body system [26, 59, 61, 62]. A large
amount of curcumin may get degraded in the presence of
detoxifying and metabolic enzymes, or it may bind to the
circulatory proteins such as albumin which may potentially
reduce its activity. Contradictorily, there have been evidences
showing that degraded products from curcumin are respon-
sible of its pharmacological activities [26, 27]. Furthermore,
it has been shown that albumin-bound curcumin exerted
similar level of activity compared to the DMSO-dissolved
curcumin in serum [103]. Of note, the curcumin degradation
and binding with physiological proteins have not been evalu-
ated in light of the curcumin antibacterial action.Whether or
not these factorswould affect the activity of curcumin, further
investigations are required. Notably, development of the
curcumin bioconjugates, nanoformulations, or derivatives
could be the key to overcome the challengesmentioned above
(summarized in Table 3). The development of modified cur-
cumin has been recently reviewed [62, 100, 101].
5. Conclusion
Curcumin has shown potent antibacterial activity and other
pharmacological actions in the past 50 years. Curcumin has
been marketed globally as a health supplement mainly for its
antioxidant and anti-inflammatory properties. In addition,
it also has high potential to be developed into an antibiotic
against S. aureus and other bacterial strains in the future.
However, the challenges mentioned in the preceding sections
should be taken into consideration to open the door for the
development of more biologically active curcumin deriva-
tives. To the best of our understanding, this is the first review
that compares and summarizes the curcumin antibacterial
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activity against S. aureus. More investigation is required in
order to better understand the broad action of curcumin prior
to develop this compound or its derivatives into a potential
antibiotic.
Competing Interests
The authors declared that there are no competing interests.
Acknowledgments
The authors would like to thank the Director General of
Health Malaysia for permission to publish this study and the
Director of the Institute forMedical Research for her support.
References
[1] A. Goel, A. B. Kunnumakkara, and B. B. Aggarwal, “Curcumin
as ‘Curecumin’: from kitchen to clinic,” Biochemical Pharmacol-
ogy, vol. 75, no. 4, pp. 787–809, 2008.
[2] M. Li, M. O. Ngadi, and Y. Ma, “Optimisation of pulsed ultra-
sonic and microwave-assisted extraction for curcuminoids by
response surface methodology and kinetic study,” Food Chem-
istry, vol. 165, pp. 29–34, 2014.
[3] K. I. Priyadarsini, “The chemistry of curcumin: from extraction
to therapeutic agent,”Molecules, vol. 19, no. 12, pp. 20091–20112,
2014.
[4] S. C. Gupta, S. Prasad, J. H. Kim et al., “Multitargeting by cur-
cumin as revealed by molecular interaction studies,” Natural
Product Reports, vol. 28, no. 12, pp. 1937–1955, 2011.
[5] R. K. Maheshwari, A. K. Singh, J. Gaddipati, and R. C. Srimal,
“Multiple biological activities of curcumin: a short review,” Life
Sciences, vol. 78, no. 18, pp. 2081–2087, 2006.
[6] S. Z. Moghadamtousi, H. A. Kadir, P. Hassandarvish, H.
Tajik, S. Abubakar, and K. Zandi, “A review on antibacterial,
antiviral, and antifungal activity of curcumin,” BioMed Research
International, vol. 2014, Article ID 186864, 12 pages, 2014.
[7] S. Bansal and S. Chhibber, “Curcumin alone and in combina-
tion with augmentin protects against pulmonary inflammation
and acute lung injury generated during Klebsiella pneumoniae
B5055-induced lung infection in BALB/c mice,” Journal of
Medical Microbiology, vol. 59, no. 4, pp. 429–437, 2010.
[8] S.-Y. Teow and S. A. Ali, “Synergistic antibacterial activity
of curcumin with antibiotics against Staphylococcus aureus,”
Pakistan Journal of Pharmaceutical Sciences, vol. 28, no. 6, pp.
2109–2114, 2015.
[9] S.-H. Mun, D.-K. Joung, Y.-S. Kim et al., “Synergistic antibacte-
rial effect of curcumin againstmethicillin-resistant Staphylococ-
cus aureus,” Phytomedicine, vol. 20, no. 8-9, pp. 714–718, 2013.
[10] A. S. Garcia-Gomes, J. A. R. Curvelo, R. M. A. Soares, and A.
Ferreira-Pereira, “Curcumin acts synergistically with flucona-
zole to sensitize a clinical isolate of Candida albicans showing
a MDR phenotype,”Medical Mycology, vol. 50, no. 1, pp. 26–32,
2012.
[11] M. Sharma, R. Manoharlal, A. S. Negi, and R. Prasad, “Syner-
gistic anticandidal activity of pure polyphenol curcumin i in
combination with azoles and polyenes generates reactive oxy-
gen species leading to apoptosis,” FEMS Yeast Research, vol. 10,
no. 5, pp. 570–578, 2010.
[12] B. B. Patel and A. P. N.Majumdar, “Synergistic role of curcumin
with current therapeutics in colorectal cancer: minireview,”
Nutrition and Cancer, vol. 61, no. 6, pp. 842–846, 2009.
[13] A. O. Boztas, O. Karakuzu, G. Galante et al., “Synergistic inter-
action of paclitaxel and curcumin with cyclodextrin polymer
complexation in human cancer cells,”Molecular Pharmaceutics,
vol. 10, no. 7, pp. 2676–2683, 2013.
[14] N. Aftab and A. Vieira, “Antioxidant activities of curcumin and
combinations of this curcuminoid with other phytochemicals,”
Phytotherapy Research, vol. 24, no. 4, pp. 500–502, 2010.
[15] O. Naksuriya and S. Okonogi, “Comparison and combination
effects on antioxidant power of curcuminwith gallic acid, ascor-
bic acid, and xanthone,”Drug Discoveries andTherapeutics, vol.
9, no. 2, pp. 136–141, 2015.
[16] N. Chainani-Wu, “Safety and anti-inflammatory activity of cur-
cumin: a component of tumeric (Curcuma longa),” Journal of
Alternative and Complementary Medicine, vol. 9, no. 1, pp. 161–
168, 2003.
[17] M. Kanai, K. Yoshimura, M. Asada et al., “A phase I/II study of
gemcitabine-based chemotherapy plus curcumin for patients
with gemcitabine-resistant pancreatic cancer,” Cancer Chemo-
therapy and Pharmacology, vol. 68, no. 1, pp. 157–164, 2011.
[18] N. Dhillon, B. B. Aggarwal, R. A. Newman et al., “Phase II trial
of curcumin in patients with advanced pancreatic cancer,”Clini-
cal Cancer Research, vol. 14, no. 14, pp. 4491–4499, 2008.
[19] S. Poapolathep, K. Imsilp, K.Machii, S. Kumagai, and A. Poapo-
lathep, “The effects of curcumin on aflatoxin B1- induced toxi-
city in rats,” Biocontrol Science, vol. 20, no. 3, pp. 171–177, 2015.
[20] D. J. Messner, G. Sivam, and K. V. Kowdley, “Curcumin reduces
the toxic effects of iron loading in rat liver epithelial cells,” Liver
International, vol. 29, no. 1, pp. 63–72, 2009.
[21] F. A. Badria, A. S. Ibrahim, A. F. Badria, and A. A. Elmarakby,
“Curcumin attenuates iron accumulation and oxidative stress in
the liver and spleen of chronic iron-overloaded rats,” PLoSONE,
vol. 10, no. 7, Article ID e0134156, 2015.
[22] M.-H. Teiten, S. Eifes, M. Dicato, and M. Diederich, “Curcu-
min-the paradigm of a multi-target natural compound with
applications in cancer prevention and treatment,” Toxins, vol.
2, no. 1, pp. 128–162, 2010.
[23] S. C. Gupta, S. Patchva,W. Koh, and B. B. Aggarwal, “Discovery
of curcumin, a component of golden spice, and its miraculous
biological activities,” Clinical and Experimental Pharmacology
and Physiology, vol. 39, no. 3, pp. 283–299, 2012.
[24] H. Zhou, C. S. Beevers, and S.Huang, “The targets of curcumin,”
Current Drug Targets, vol. 12, no. 3, pp. 332–347, 2011.
[25] C. Schneider, O. N. Gordon, R. L. Edwards, and P. B. Luis,
“Degradation of curcumin: from mechanism to biological
implications,” Journal of Agricultural and Food Chemistry, vol.
63, no. 35, pp. 7606–7614, 2015.
[26] L. Shen and H.-F. Ji, “The pharmacology of curcumin: Is it the
degradation products?” Trends in Molecular Medicine, vol. 18,
no. 3, pp. 138–144, 2012.
[27] L. Shen, C.-C. Liu, C.-Y. An, and H.-F. Ji, “How does curcumin
work with poor bioavailability? Clues from experimental and
theoretical studies,” Scientific Reports, vol. 6, Article ID 20872,
2016.
[28] D. Ghosh, D. Bagchi, and T. Konishi, Clinical Aspects of Func-
tional Foods and Nutraceuticals, CRC Press/Taylor and Francis
Group, 2014.
[29] E. Schraufsta¨tter and H. Bernt, “Antibacterial action of cur-
cumin and related compounds,” Nature, vol. 164, no. 4167, pp.
456–457, 1949.
8 Journal of Tropical Medicine
[30] P. Tyagi, M. Singh, H. Kumari, A. Kumari, and K. Mukhopad-
hyay, “Bactericidal activity of curcumin I is associated with
damaging of bacterial membrane,” PLoS ONE, vol. 10, no. 3,
Article ID e0121313, 2015.
[31] K. Moghaddam, M. Iranshahi, M. Yazdi, and A. Shahverdi,
“The combination effect of curcumin with different antibiotics
against Staphylococcus aureus,” International Journal of Green
Pharmacy, vol. 3, no. 2, pp. 141–143, 2009.
[32] S.-H. Mun, S.-B. Kim, R. Kong et al., “Curcumin reverse methi-
cillin resistance in Staphylococcus aureus,”Molecules, vol. 19, no.
11, pp. 18283–18295, 2014.
[33] S. Y. C. Tong, J. S. Davis, E. Eichenberger, T. L. Holland, and
V. G. Fowler, “Staphylococcus aureus infections: epidemiology,
pathophysiology, clinical manifestations, and management,”
Clinical Microbiology Reviews, vol. 28, no. 3, pp. 603–661, 2015.
[34] H. W. Boucher and G. R. Corey, “Epidemiology of methicillin-
resistant Staphylococcus aureus,”Clinical Infectious Diseases, vol.
46, supplement 5, pp. S344–S349, 2008.
[35] E. Klein, D. L. Smith, and R. Laxminarayan, “Hospitaliza-
tions and deaths caused by methicillin-resistant Staphylococcus
aureus, United States, 1999-2005,” Emerging Infectious Diseases,
vol. 13, no. 12, pp. 1840–1846, 2007.
[36] B. Tarai, P. Das, and D. Kumar, “Recurrent challenges for clini-
cians: emergence ofmethicillin-resistant Staphylococcus aureus,
vancomycin resistance, and current treatment options,” Journal
of Laboratory Physicians, vol. 5, no. 2, pp. 71–78, 2013.
[37] C. L. Ventola, “The antibiotic resistance crisis—part 1: causes
and threats,” Pharmacy andTherapeutics, vol. 40, no. 4, pp. 277–
283, 2015.
[38] R. V. Rasmussen, V. G. Fowler Jr., R. Skov, and N. E. Bruun,
“Future challenges and treatment of Staphylococcus aureus bac-
teremia with emphasis on MRSA,” Future Microbiology, vol. 6,
no. 1, pp. 43–56, 2011.
[39] A. P. D. Ribeiro, A. C. Pavarina, L. N. Dovigo et al., “Photo-
toxic effect of curcumin on methicillin-resistant Staphylococcus
aureus and L929 fibroblasts,” Lasers in Medical Science, vol. 28,
no. 2, pp. 391–398, 2013.
[40] J. Wang, X. Zhou, W. Li, X. Deng, Y. Deng, and X. Niu, “Cur-
cumin protects mice from Staphylococcus aureus pneumonia
by interfering with the self-assembly process of 𝛼-hemolysin,”
Scientific Reports, vol. 6, Article ID 28254, 2016.
[41] N. K. Sasidharan, S. R. Sreekala, J. Jacob, and B. Nambisan, “In
vitro synergistic effect of curcumin in combination with third
generation cephalosporins against bacteria associated with
infectious diarrhea,” BioMed Research International, vol. 2014,
Article ID 561456, 8 pages, 2014.
[42] S. Tajbakhsh, K. Mohammadi, I. Deilami et al., “Antibacterial
activity of indium curcumin and indium diacetylcurcumin,”
African Journal of Biotechnology, vol. 7, no. 21, pp. 3832–3835,
2008.
[43] K. Mohammadi, K. H. Thompson, B. O. Patrick et al., “Syn-
thesis and characterization of dual function vanadyl, gallium
and indium curcumin complexes for medicinal applications,”
Journal of Inorganic Biochemistry, vol. 99, no. 11, pp. 2217–2225,
2005.
[44] D. Rai, J. K. Singh, N. Roy, and D. Panda, “Curcumin inhibits
FtsZ assembly: an attractive mechanism for its antibacterial
activity,” Biochemical Journal, vol. 410, no. 1, pp. 147–155, 2008.
[45] G. Y. Liu, “Molecular pathogenesis of Staphylococcus aureus
infection,” Pediatric Research, vol. 65, no. 5, part 2, pp. 71R–77R,
2009.
[46] L. G.Miller and S. L. Kaplan, “Staphylococcus aureus: a commu-
nity pathogen,” Infectious Disease Clinics of North America, vol.
23, no. 1, pp. 35–52, 2009.
[47] H. Gunes, D. Gulen, R. Mutlu, A. Gumus, T. Tas, and A. E.
Topkaya, “Antibacterial effects of curcumin: an in vitro mini-
mum inhibitory concentration study,” Toxicology and Industrial
Health, vol. 32, no. 2, pp. 246–250, 2016.
[48] A. Kali, D. Bhuvaneshwar, P. V. Charles, and K. Seetha, “Anti-
bacterial synergy of curcumin with antibiotics against biofilm
producing clinical bacterial isolates,” Journal of Basic and
Clinical Pharmacy, vol. 7, no. 3, pp. 93–96, 2016.
[49] S. Sandikci Altunatmaz, F. Yilmaz Aksu, G. Issa, B. Basaran
Kahraman,D.Dulger Altiner, and S. Buyukunal, “Antimicrobial
effects of curcumin against L. monocytogenes, S. aureus, S.
Typhimurium and E. coliO157 :H7 pathogens in minced meat,”
Veterina´rnı´ Medic´ına, vol. 61, no. 5, pp. 256–262, 2016.
[50] C. E. Goodpasture and F. E. Arrighi, “Effects of food seasonings
on the cell cycle and chromosome morphology of mammalian
cells in vitro with special reference to turmeric,” Food and
Cosmetics Toxicology, vol. 14, no. 1, pp. 9–14, 1976.
[51] J. Cao, L. Jia, H.-M. Zhou, Y. Liu, and L.-F. Zhong, “Mitochon-
drial and nuclear DNA damage induced by curcumin in human
hepatomaG2 cells,”Toxicological Sciences, vol. 91, no. 2, pp. 476–
483, 2006.
[52] P. Urbina-Cano, L. Bobadilla-Morales, M. A. Ramı´rez-Herrera
et al., “DNA damage in mouse lymphocytes exposed to curcu-
min and copper,” Journal of Applied Genetics, vol. 47, no. 4, pp.
377–382, 2006.
[53] R. D. Verschoyle, W. P. Steward, and A. J. Gescher, “Putative
cancer chemopreventive agents of dietary origin-how safe are
they?” Nutrition and Cancer, vol. 59, no. 2, pp. 152–162, 2007.
[54] National Toxicology Program, “NTP toxicology and carcino-
genesis studies of turmeric oleoresin (CAS No. 8024-37-1)
(major component 79%-85% curcumin, CAS No. 458-37-7) in
F344/N rats and B6C3F1 mice (feed studies),” National Toxicol-
ogy Program Technical Report Series, vol. 427, pp. 1–275, 1993.
[55] S. T. Dance-Barnes, N. D. Kock, J. E. Moore et al., “Lung tumor
promotion by curcumin,” Carcinogenesis, vol. 30, no. 6, pp.
1016–1023, 2009.
[56] Y. Jiao, J. Wilkinson IV, X. Di et al., “Curcumin, a cancer
chemopreventive and chemotherapeutic agent, is a biologically
active iron chelator,” Blood, vol. 113, no. 2, pp. 462–469, 2009.
[57] R. Appiah-Opong, J. N. M. Commandeur, B. van Vugt-Lussen-
burg, and N. P. E. Vermeulen, “Inhibition of human recombi-
nant cytochrome P450s by curcumin and curcumin decompo-
sition products,” Toxicology, vol. 235, no. 1-2, pp. 83–91, 2007.
[58] R. Thapliyal and G. B. Maru, “Inhibition of cytochrome P450
isozymes by curcumins in vitro and in vivo,” Food and Chemical
Toxicology, vol. 39, no. 6, pp. 541–547, 2001.
[59] B. T. Kurien, A. Singh, H. Matsumoto, and R. H. Scofield,
“Improving the solubility and pharmacological efficacy of cur-
cumin by heat treatment,” Assay and Drug Development Tech-
nologies, vol. 5, no. 4, pp. 567–576, 2007.
[60] B. T. Kurien and R. H. Scofield, “Heat-solubilized curcumin
should be considered in clinical trials for increasing bioavail-
ability,” Clinical Cancer Research, vol. 15, no. 2, p. 747, 2009.
[61] P.Anand,A. B.Kunnumakkara, R.A.Newman, andB. B.Aggar-
wal, “Bioavailability of curcumin: problems and promises,”
Molecular Pharmaceutics, vol. 4, no. 6, pp. 807–818, 2007.
[62] S. Prasad, A. K. Tyagi, and B. B. Aggarwal, “Recent develop-
ments in delivery, bioavailability, absorption and metabolism
Journal of Tropical Medicine 9
of curcumin: the golden pigment from golden spice,” Cancer
Research and Treatment, vol. 46, no. 1, pp. 2–18, 2014.
[63] T. Matsui, J. Yamane, N. Mogi et al., “Structural reorganization
of the bacterial cell-division protein FtsZ from Staphylococcus
aureus,” Acta Crystallographica Section D: Biological Crystallog-
raphy, vol. 68, no. 9, pp. 1175–1188, 2012.
[64] P. Singh and D. Panda, “FtsZ inhibition: a promising approach
for anti-staphylococcal therapy,” Drug News and Perspectives,
vol. 23, no. 5, pp. 295–304, 2010.
[65] P. Gul and J. Bakht, “Antimicrobial activity of turmeric extract
and its potential use in food industry,” Journal of Food Science
and Technology, vol. 52, no. 4, pp. 2272–2279, 2015.
[66] A. Gupta, S. Mahajan, and R. Sharma, “Evaluation of antimi-
crobial activity of Curcuma longa rhizome extract against Sta-
phylococcus aureus,” Biotechnology Reports, vol. 6, pp. 51–55,
2015.
[67] J. E. Foweraker, C. R. Laughton, D. F. Brown, and D. Bilton,
“Comparison ofmethods to test antibiotic combinations against
heterogeneous populations of multiresistant Pseudomonas
aeruginosa from patients with acute infective exacerbations in
cystic fibrosis,”Antimicrobial Agents and Chemotherapy, vol. 53,
no. 11, pp. 4809–4815, 2009.
[68] G. S. Sen, S. Mohanty, D. M. S. Hossain et al., “Curcumin
enhances the efficacy of chemotherapy by tailoring p65NF𝜅B-
p300 cross-talk in favor of p53–p300 in breast cancer,” The
Journal of Biological Chemistry, vol. 286, no. 49, pp. 42232–
42247, 2011.
[69] V. Ruiz de Porras, S. Bystrup, A. Mart´ınez-Cardu´s et al., “Cur-
cumin mediates oxaliplatin-acquired resistance reversion in
colorectal cancer cell lines through modulation of CXC-Chem-
okine/NF-𝜅B signalling pathway,” Scientific Reports, vol. 6,
article 24675, 2016.
[70] B. Sivanantham, S. Sethuraman, and U. M. Krishnan, “Combi-
natorial effects of curcumin with an anti-neoplastic agent on
head and neck squamous cell carcinoma through the regula-
tion of EGFR-ERK1/2 and apoptotic signaling pathways,” ACS
Combinatorial Science, vol. 18, no. 1, pp. 22–35, 2016.
[71] H. Wahl, L. Tan, K. Griffith, M. Choi, and J. R. Liu, “Curcumin
enhances Apo2L/TRAIL-induced apoptosis in chemoresistant
ovarian cancer cells,” Gynecologic Oncology, vol. 105, no. 1, pp.
104–112, 2007.
[72] S. Saha, A.Adhikary, P. Bhattacharyya, T.Das, andG. Sa, “Death
by design: where curcumin sensitizes drug-resistant tumours,”
Anticancer Research, vol. 32, no. 7, pp. 2567–2584, 2012.
[73] T. Nabekura, “Overcoming multidrug resistance in human
cancer cells by natural compounds,” Toxins, vol. 2, no. 6, pp.
1207–1224, 2010.
[74] R. Ko¨ck, K. Becker, B. Cookson et al., “Methicillin-resistant
Staphylococcus aureus (MRSA): burden of disease and control
challenges in Europe,” Euro Surveillance, vol. 15, no. 41, Article
ID 19688, 2010.
[75] S. J. Peacock and G. K. Paterson, “Mechanisms of methicillin
resistance in Staphylococcus aureus,”Annual Review of Biochem-
istry, vol. 84, pp. 577–601, 2015.
[76] P. Balan, G. Mal, S. Das, and H. Singh, “Synergistic and additive
antimicrobial activities of curcumin, Manuka honey and whey
proteins,” Journal of Food Biochemistry, vol. 40, no. 5, pp. 647–
654, 2016.
[77] G. Sharma, K. Raturi, S. Dang, S. Gupta, and R. Gabrani, “Com-
binatorial antimicrobial effect of curcumin with selected phy-
tochemicals on Staphylococcus epidermidis,” Journal of Asian
Natural Products Research, vol. 16, no. 5, pp. 535–541, 2014.
[78] K. Chaieb, B. Kouidhi, H. Jrah, K.Mahdouani, andA. Bakhrouf,
“Antibacterial activity of Thymoquinone, an active principle
of Nigella sativa and its potency to prevent bacterial biofilm
formation,” BMCComplementary and AlternativeMedicine, vol.
11, article 29, 2011.
[79] D.-K. Joung, H. Joung, D.-W. Yang et al., “Synergistic effect of
rhein in combinationwith ampicillin or oxacillin againstmethi-
cillin-resistant Staphylococcus aureus,” Experimental andTher-
apeutic Medicine, vol. 3, no. 4, pp. 608–612, 2012.
[80] Y.-S. Lee, O.-H. Kang, J.-G. Choi et al., “Synergistic effect of
emodin in combination with ampicillin or oxacillin against
methicillin-resistant Staphylococcus aureus,” Pharmaceutical
Biology, vol. 48, no. 11, pp. 1285–1290, 2010.
[81] H.-K. Kang, H.-Y. Kim, and J.-D. Cha, “Synergistic effects
between silibinin and antibiotics on methicillin-resistant Sta-
phylococcus aureus isolated from clinical specimens,” Biotech-
nology Journal, vol. 6, no. 11, pp. 1397–1408, 2011.
[82] P. Joshi, S. Singh, A. Wani et al., “Osthol and curcumin as
inhibitors of humanPgp andmultidrug effluxpumps of Staphyl-
ococcus aureus: reversing the resistance against frontline anti-
bacterial drugs,”MedChemComm, vol. 5, no. 10, pp. 1540–1547,
2014.
[83] H. Akiyama, K. Fujii, O. Yamasaki, T. Oono, and K. Iwatsuki,
“Antibacterial action of several tannins against Staphylococcus
aureus,” Journal of Antimicrobial Chemotherapy, vol. 48, no. 4,
pp. 487–491, 2001.
[84] W.-H. Zhao, Z.-Q. Hu, S. Okubo, Y. Hara, and T. Shimamura,
“Mechanism of synergy between epigallocatechin gallate and
𝛽-lactams against methicillin-resistant Staphylococcus aureus,”
Antimicrobial Agents and Chemotherapy, vol. 45, no. 6, pp. 1737–
1742, 2001.
[85] S. C. Gupta, S. Patchva, and B. B. Aggarwal, “Therapeutic roles
of curcumin: lessons learned from clinical trials,”AAPS Journal,
vol. 15, no. 1, pp. 195–218, 2013.
[86] E. Burgos-Moro´n, J. M. Caldero´n-Montan˜o, J. Salvador, A.
Robles, and M. Lo´pez-La´zaro, “The dark side of curcumin,”
International Journal of Cancer, vol. 126, no. 7, pp. 1771–1775,
2010.
[87] S. J. McNally, E. M. Harrison, J. A. Ross, O. J. Garden, and S. J.
Wigmore, “Curcumin induces heme oxygenase 1 through gen-
eration of reactive oxygen species, p38 activation and phos-
phatase inhibition,” International Journal ofMolecularMedicine,
vol. 19, no. 1, pp. 165–172, 2007.
[88] J. Kang, J. Chen, Y. Shi, J. Jia, and Y. Zhang, “Curcumin-induced
histone hypoacetylation: the role of reactive oxygen species,”
Biochemical Pharmacology, vol. 69, no. 8, pp. 1205–1213, 2005.
[89] T. Atsumi, S. Fujisawa, and K. Tonosaki, “Relationship between
intracellular ROS production andmembranemobility in curcu-
min- and tetrahydrocurcumin-treated human gingival fibrob-
lasts and human submandibular gland carcinoma cells,” Oral
Diseases, vol. 11, no. 4, pp. 236–242, 2005.
[90] R. A. Sharma, S. A. Euden, S. L. Platton et al., “Phase I clinical
trial of oral curcumin: biomarkers of systemic activity and
compliance,” Clinical Cancer Research, vol. 10, no. 20, pp. 6847–
6854, 2004.
[91] S. Balaji and B. Chempakam, “Toxicity prediction of com-
pounds from turmeric (Curcuma longa L),” Food and Chemical
Toxicology, vol. 48, no. 10, pp. 2951–2959, 2010.
[92] S. Manju and K. Sreenivasan, “Conjugation of curcumin onto
hyaluronic acid enhances its aqueous solubility and stability,”
Journal of Colloid and Interface Science, vol. 359, no. 1, pp. 318–
325, 2011.
10 Journal of Tropical Medicine
[93] S. Dey and K. Sreenivasan, “Conjugation of curcumin onto
alginate enhances aqueous solubility and stability of curcumin,”
Carbohydrate Polymers, vol. 99, pp. 499–507, 2014.
[94] M. Esmaili, S. M. Ghaffari, Z. Moosavi-Movahedi et al., “Beta
casein-micelle as a nano vehicle for solubility enhancement of
curcumin; food industry application,” LWT—Food Science and
Technology, vol. 44, no. 10, pp. 2166–2172, 2011.
[95] M. G. O’Toole, R. M. Henderson, P. A. Soucy et al., “Curcumin
encapsulation in submicrometer spray-dried chitosan/Tween
20 particles,” Biomacromolecules, vol. 13, no. 8, pp. 2309–2314,
2012.
[96] M. H. Ucisik, S. Ku¨pcu¨, B. Schuster, and U. B. Sleytr, “Charac-
terization of CurcuEmulsomes: nanoformulation for enhanced
solubility and delivery of curcumin,” Journal of Nanobiotechnol-
ogy, vol. 11, no. 1, article 37, 2013.
[97] K. Pan, Q. Zhong, and S. J. Baek, “Enhanced dispersibility and
bioactivity of curcumin by encapsulation in casein nanocap-
sules,” Journal of Agricultural and Food Chemistry, vol. 61, no.
25, pp. 6036–6043, 2013.
[98] C.Thomas, L. S. Pillai, and L. Krishnan, “Evaluation of albumin-
ated curcumin as soluble drug form to control growth of cancer
cells in vitro,” Journal of Cancer Therapy, vol. 5, no. 7, pp. 723–
734, 2014.
[99] T. H. Kim, H. H. Jiang, Y. S. Youn et al., “Preparation and chara-
cterization of water-soluble albumin-bound curcumin nano-
particles with improved antitumor activity,” International Jour-
nal of Pharmaceutics, vol. 403, no. 1-2, pp. 285–291, 2011.
[100] M. M. Yallapu, M. Jaggi, and S. C. Chauhan, “Curcumin nano-
formulations: a future nanomedicine for cancer,” Drug Discov-
ery Today, vol. 17, no. 1-2, pp. 71–80, 2012.
[101] M. M. Yallapu, M. Jaggi, and S. C. Chauhan, “Curcumin nano-
medicine: a road to cancer therapeutics,” Current Pharmaceuti-
cal Design, vol. 19, no. 11, pp. 1994–2010, 2013.
[102] N. Ghalandarlaki, A. M. Alizadeh, and S. Ashkani-Esfahani,
“Nanotechnology-applied curcumin for different diseases ther-
apy,” BioMed Research International, vol. 2014, Article ID
394264, 23 pages, 2014.
[103] W. W. Quitschke, “Differential solubility of curcuminoids in
serum and albumin solutions: implications for analytical and
therapeutic applications,” BMC Biotechnology, vol. 8, article 84,
2008.
Submit your manuscripts at
http://www.hindawi.com
Stem Cells
International
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
MEDIATORS
INFLAMMATION
of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Behavioural 
Neurology
Endocrinology
International Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Disease Markers
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
BioMed 
Research International
Oncology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Oxidative Medicine and 
Cellular Longevity
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
PPAR Research
The Scientific 
World Journal
Hindawi Publishing Corporation 
http://www.hindawi.com Volume 2014
Immunology Research
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Journal of
Obesity
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
 Computational and  
Mathematical Methods 
in Medicine
Ophthalmology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Diabetes Research
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Research and Treatment
AIDS
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Gastroenterology 
Research and Practice
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Parkinson’s 
Disease
Evidence-Based 
Complementary and 
Alternative Medicine
Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com
